ALK(002940)2024-10-29 10:08Financial Performance - The company's revenue for Q3 2024 was ¥274,148,813.35, a decrease of 20.23% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥18,164,707.17, representing a decline of 426.40% year-on-year[2]. - Total operating revenue for the period was CNY 1,121,560,480.84, a decrease of 5.5% compared to CNY 1,186,981,982.04 in the previous period[18]. - The net profit attributable to shareholders decreased to CNY 562,429,430.17 from CNY 605,937,948.93, a decline of 7.2%[17]. - In Q3 2024, the company reported a net profit of CNY 106.73 million, a decrease of 24.2% compared to CNY 140.89 million in Q3 2023[19]. - Operating profit for Q3 2024 was CNY 107.63 million, a decline of 30.3% from CNY 154.51 million in Q3 2023[19]. - The total comprehensive income for Q3 2024 was CNY 106.73 million, compared to CNY 140.89 million in Q3 2023[20]. - The basic and diluted earnings per share for Q3 2024 were CNY 0.25, down from CNY 0.54 in the same period last year[20]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥262,316,880.61, down 17.05% from the previous year[2]. - The net increase in cash and cash equivalents was -¥229,061,372.19, a decrease of 190.30% year-on-year[8]. - Cash flow from operating activities for Q3 2024 was CNY 262.32 million, down 17.0% from CNY 316.23 million in Q3 2023[21]. - The cash and cash equivalents at the end of the period amounted to 623,552,676.14 CNY, down from 982,568,546.95 CNY at the end of the previous year[22]. - The company experienced a net decrease in cash and cash equivalents of -229,061,372.19 CNY, contrasting with an increase of 253,671,044.83 CNY in the prior year[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,083,114,317.96, an increase of 2.09% compared to the end of the previous year[2]. - The company's current assets totaled CNY 1,602,419,421.11, an increase of 2.5% from CNY 1,561,930,701.37[16]. - Total liabilities reached CNY 1,294,752,330.19, an increase of 9.0% compared to CNY 1,187,721,064.95[17]. - The company's total assets amounted to CNY 3,083,114,317.96, up from CNY 3,019,990,734.37, reflecting a growth of 2.1%[17]. Investments and R&D - The company's R&D expenses for the first nine months of 2024 increased by 66.87% to ¥164,442,741.83 compared to the same period in 2023[7]. - The investment income for the first nine months of 2024 was -¥2,211,494.10, a decline of 1111.17% compared to the previous year[7]. - The company holds a 19% stake in the newly established Hangzhou Tiankang Chuangji Pharmaceutical Technology Co., Ltd.[13]. - The company has entered into a strategic cooperation agreement with Shanghai Qinhuli Biotechnology Co., Ltd. for the development of a drug based on the QHL-1618 molecule, granting exclusive rights for research, production, and commercialization[11]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,712[9]. - The largest shareholder, Shenzhou JunTai Investment Co., Ltd., holds 35.44% of the shares, amounting to 71,485,000 shares[10]. - The top ten shareholders collectively hold significant stakes, with the top three shareholders controlling 60.30% of the company[10]. - The company has not reported any changes in the participation of the top ten shareholders in margin financing and securities lending[11]. Legal and Compliance - The company is currently involved in a civil lawsuit regarding patent infringement related to sacubitril/valsartan sodium tablets, with a claim for damages amounting to 500,000 RMB[14]. - The company’s third-quarter report was not audited[23]. Other Financial Metrics - The company reported a decrease in the equity attributable to shareholders by 4.88% to ¥1,508,787,977.69 compared to the end of the previous year[2]. - The company recorded a decrease in other income to CNY 16.44 million in Q3 2024 from CNY 28.03 million in Q3 2023[19]. - The company’s interest expenses increased to CNY 13.37 million in Q3 2024 from CNY 10.25 million in Q3 2023[19]. - The company reported a goodwill of CNY 312,941,911.25, unchanged from the previous period[16].